Mayne loses UK appeal on generic cancer drug
Monday, 21 February, 2005
Mayne Group will book a AUD$5 million one-off charge in its first-half results after a UK appeal court ruled its version of the cancer drug epirubicin infringed a patent on the original drug.
Mayne had been looking to win approval to sell its formulation of epirubicin, used in breast cancer chemotherapy, before the patent held by Pharmacia Italia, a unit of Pfizer, expired in June 2006.
The English High Court had ruled in favour of Mayne last October, but the Court of Appeal overturned the ruling on a point of law.
Mayne said the AUD$5 million charge it will record reflects the top end of estimated legal and other costs associated with the UK litigation. Analysts expect Mayne to report a net profit of around AUD$35 million before one-offs for the first-half when it releases its results on February 23.
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
